Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash & Equivalents (2016 - 2025)

Cumberland Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 36.29% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, down 36.29%, while the annual FY2025 figure was $11.4 million, 36.29% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $11.4 million at Cumberland Pharmaceuticals, down from $15.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $27.0 million in Q4 2021 and bottomed at $11.4 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $18.2 million (2022), against an average of $19.0 million.
  • The largest annual shift saw Cash & Equivalents increased 13.2% in 2024 before it tumbled 36.29% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $27.0 million in 2021, then decreased by 26.93% to $19.8 million in 2022, then fell by 6.33% to $18.5 million in 2023, then decreased by 2.94% to $18.0 million in 2024, then plummeted by 36.29% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Cash & Equivalents are $11.4 million (Q4 2025), $15.2 million (Q3 2025), and $16.1 million (Q2 2025).